New heart failure guidance stresses four pillars of management

ARNI now perferred over ACEi, and SGLT2i makes an entrance
2
8 August 2022
Save
Please login to bookmark Close
4 pillars

New Australian guidance on heart failure management recommends a four-drug-class approach in patients with heart failure with reduced ejection fraction (HFrEF).

The consensus statement on the current pharmacological prevention and management of heart failure prioritises the following four drug classes in combination in all patients with heart failure with reduced left ventricular ejection fraction (LVEF ≤ 40%) (HFrEF).

The evidence also supports this therapy combination in patients with heart failure with mildly reduced LVEF (41-49%) (HFmrEF).

The consensus statement, published in the Medical Journal of Australia, augments the current 2018 NHFA/CSANZ heart failure guidelines and mirrors many of the recommendations from the latest European and US guidelines.

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Content that breaches the privacy of other individuals
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .